Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api
{ "count": 24395, "next": "http://api.gregory-ms.com/articles/?format=api&page=2", "previous": null, "results": [ { "article_id": 283237, "title": "Dysregulation of innate immune signaling in animal models of spinal muscular atrophy", "summary": null, "link": "https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-024-01888-z", "published_date": "2024-04-24T23:00:00Z", "source": "BioMedCentral", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": null, "ml_prediction_lr": null, "ml_prediction_lsvc": null, "discovery_date": "2024-04-25T12:26:58.445600Z", "noun_phrases": null, "doi": "10.1186/s12915-024-01888-z", "access": "restricted", "takeaways": null, "categories": [] }, { "article_id": 283235, "title": "Roles of TRP and PIEZO receptors in autoimmune diseases", "summary": "Autoimmune diseases are pathological autoimmune reactions in the body caused by various factors, which can lead to tissue damage and organ dysfunction. They can be divided into organ-specific and systemic autoimmune diseases. These diseases usually involve various body systems, including the blood, muscles, bones, joints and soft tissues. The transient receptor potential (TRP) and PIEZO receptors, which resulted in David Julius and Ardem Patapoutian winning the Nobel Prize in Physiology or...", "link": "https://pubmed.ncbi.nlm.nih.gov/38659380/?fc=20210216052009&ff=20240425112532&v=2.18.0.post9+e462414", "published_date": "2024-04-25T10:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-25T11:25:47.684338Z", "noun_phrases": null, "doi": "10.1017/erm.2023.23", "access": "restricted", "takeaways": "Autoimmune diseases are pathological autoimmune reactions in the body caused by various factors. They can be divided into organ-specific and systemic autoimmune diseases. The diseases usually involve", "categories": [] }, { "article_id": 283234, "title": "A role for vessel-associated extracellular matrix proteins in multiple sclerosis pathology", "summary": "Multiple sclerosis (MS) is unsurpassed for its clinical and pathological hetherogeneity, but the biological determinants of this variability are unknown. HLA-DRB1*15, the main genetic risk factor for MS, influences the severity and distribution of MS pathology. This study set out to unravel the molecular determinants of the heterogeneity of MS pathology in relation to HLA-DRB1*15 status. Shotgun proteomics from a discovery cohort of MS spinal cord samples segregated by HLA-DRB*15 status revealed...", "link": "https://pubmed.ncbi.nlm.nih.gov/38659387/?fc=20210216052009&ff=20240425112532&v=2.18.0.post9+e462414", "published_date": "2024-04-25T10:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-25T11:25:46.835366Z", "noun_phrases": null, "doi": "10.1111/bpa.13263", "access": "restricted", "takeaways": "HLA-DRB1*15 is the main genetic risk factor for MS. Proteomics from a discovery cohort of MS spinal cord samples segregated by HLA", "categories": [] }, { "article_id": 283233, "title": "People with newly diagnosed multiple sclerosis benefit from a complex preventative intervention—a single group prospective study with follow up", "summary": "<jats:sec><jats:title>Background</jats:title><jats:p>Newly diagnosed people with multiple sclerosis frequently report fatigue, pain, depression and anxiety. Preventative programmes may be beneficial, but there is limited evidence of their effectiveness, especially long-term follow-up.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The programme consisted of 6-month face to face intervention (an introductory workshop, psychology-led group sessions and individual physical therapy) followed by 6-month self-guided therapy. Outcome measures were taken at baseline, 6 and 12 months. Primary outcomes measures were self-report questionnaires for fatigue, satisfaction with life and disease acceptance. Secondary outcomes were spirometry, spiroergometric parameters and neuroactive steroid levels.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>From 22 participants enrolled, 17 completed the first 6 months and 13 the follow-up. Fatigue measured on the Fatigue scale for motor and cognitive functions decreased significantly at 6 months (<jats:italic>p</jats:italic> = 0.035) and at follow-up (<jats:italic>p</jats:italic> = 0.007). The Modified Fatigue Impact Scale (<jats:italic>p</jats:italic> = 0.035) and Satisfaction With Life Scale (<jats:italic>p</jats:italic> = 0.007) significantly increased at follow-up. Spirometry, spiroergometric parameters, steroid hormones and neuroactive steroids levels did not change significantly.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This programme reduces fatigue and improves satisfaction with life in this patient group with improvements sustained at 12 months. People who participated more frequently showed greater benefit.</jats:p></jats:sec><jats:sec><jats:title>Clinical rehabilitation impact</jats:title><jats:p>The paper describes the effects of a complex preventative intervention for people with newly diagnosed Multiple Sclerosis. The study found that this programme reduces fatigue and improves satisfaction with life with long-term benefit (at 12-month follow up). The individuals who participated less frequently experienced fewer benefits.</jats:p></jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/38660088/?fc=20210216052009&ff=20240425112532&v=2.18.0.post9+e462414", "published_date": "2024-04-25T10:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Neurology", "authors": [ { "author_id": 348915, "given_name": "Natália", "family_name": "Hrušková", "ORCID": null, "country": null }, { "author_id": 348916, "given_name": "Kateřina", "family_name": "Berchová Bímová", "ORCID": null, "country": null }, { "author_id": 193539, "given_name": "Angela", "family_name": "Davies Smith", "ORCID": "http://orcid.org/0000-0002-2358-9239", "country": null }, { "author_id": 348917, "given_name": "Tereza", "family_name": "Škodová", "ORCID": null, "country": null }, { "author_id": 348918, "given_name": "Marie", "family_name": "Bičíková", "ORCID": null, "country": null }, { "author_id": 348919, "given_name": "Lucie", "family_name": "Kolátorová", "ORCID": null, "country": null }, { "author_id": 348920, "given_name": "Ivana", "family_name": "Štětkářová", "ORCID": null, "country": null }, { "author_id": 348921, "given_name": "Ľuba", "family_name": "Brožek", "ORCID": null, "country": null }, { "author_id": 348922, "given_name": "Alena", "family_name": "Javůrková", "ORCID": null, "country": null }, { "author_id": 348923, "given_name": "Gabriela", "family_name": "Angelová", "ORCID": null, "country": null }, { "author_id": 175092, "given_name": "Kamila", "family_name": "Řasová", "ORCID": "http://orcid.org/0000-0002-3201-1770", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-25T11:25:45.426043Z", "noun_phrases": null, "doi": "10.3389/fneur.2024.1373401", "access": "open", "takeaways": "There is limited evidence of the effectiveness of preventative programmes. The study found that this programme reduces fatigue and improves satisfaction with life with long-term benefit at 12 months.", "categories": [] }, { "article_id": 283232, "title": "Risk of secondary immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis", "summary": "<jats:sec><jats:title>Object</jats:title><jats:p>The purpose of this study was to evaluate the risk of secondary immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab through a meta-analysis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We searched databases including PubMed, Web of Science, OVID and EMBASE for studies reporting changes in platelet levels in MS patients treated with alemtuzumab from their inception until May 2023 and performed a meta-analysis. Information and data were screened and extracted by two researchers. The inclusion and exclusion criteria were established according to the PICOS principle. The obtained data were analyzed using the R software meta package and the quality assessment was conducted using Newcastle-Ottawa Scale (NOS). The causes of heterogeneity were analyzed using subgroup analysis and sensitivity analysis. Publication bias was evaluated using funnel plots and Egger test.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 15 studies were included, encompassing 1,729 multiple sclerosis patients. Meta-analysis of overall secondary ITP in the included studies yielded a pooled rate of 0.0243. The overall incidence of secondary autoimmune events was 0.2589. In addition, subgroup analysis was applied using study regions and study types. The results showed that the incidence rate of secondary ITP in Europe was about 0.0207, while the incidence of autoimmune events (AEs) was 0.2158. The incidence rate of secondary ITP and AEs in North America was significantly higher than in Europe, being 0.0352 and 0.2622. And the analysis showed that the incidence rates of secondary ITP and AEs in prospective studies were 0.0391 and 0.1771. Retrospective studies had an incidence rate of secondary ITP at 2.16, and an incidence rate of AEs at 0.2743.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This study found that there was a certain incidence of Immune thrombocytopenia in multiple sclerosis patients after treatment with alemtuzumab. Alemtuzumab may have some interference with platelet levels, and the mechanism may be associated with Treg cells. But due to the absence of a control group in the included literature, we cannot determine the specific impact of Alemtuzumab on platelet levels in patients with MS. Therefore, clinical physicians should perform a comprehensive assessment of the patient’s benefit-to-risk ratio before initiating alemtuzumab.</jats:p></jats:sec><jats:sec><jats:title>Systematic Review Registration</jats:title><jats:p>Inplasy website, DOI number is <jats:ext-link>10.37766/inplasy2024.3.0007</jats:ext-link>.</jats:p></jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/38660089/?fc=20210216052009&ff=20240425112532&v=2.18.0.post9+e462414", "published_date": "2024-04-25T10:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Neurology", "authors": [ { "author_id": 348907, "given_name": "Yuying", "family_name": "Sun", "ORCID": null, "country": null }, { "author_id": 348908, "given_name": "Zhimei", "family_name": "Liu", "ORCID": null, "country": null }, { "author_id": 348909, "given_name": "Jianguo", "family_name": "Yang", "ORCID": null, "country": null }, { "author_id": 348910, "given_name": "Qingqing", "family_name": "Jia", "ORCID": null, "country": null }, { "author_id": 348911, "given_name": "Jinglong", "family_name": "Sun", "ORCID": null, "country": null }, { "author_id": 156033, "given_name": "Lei", "family_name": "Wang", "ORCID": "http://orcid.org/0000-0001-5331-0318", "country": null }, { "author_id": 348912, "given_name": "Fengjiao", "family_name": "Liang", "ORCID": null, "country": null }, { "author_id": 348913, "given_name": "Shiyuan", "family_name": "Song", "ORCID": null, "country": null }, { "author_id": 348914, "given_name": "Kaixi", "family_name": "Wang", "ORCID": null, "country": null }, { "author_id": 270420, "given_name": "Xia", "family_name": "Zhou", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-25T11:25:43.999908Z", "noun_phrases": null, "doi": "10.3389/fneur.2024.1375615", "access": "open", "takeaways": "There was an incidence of secondary immune thrombocytopenia in MS patients treated with alemtuzumab from their inception until May 2023. The incidence rate of secondary ITP in Europe was about 0.0207, while the incidence of autoimmune events (AEs) was 0.2158. In North America, the incidence rate was significantly higher.", "categories": [ { "category_id": 2, "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/", "category_name": "Alemtuzumab", "category_slug": "alemtuzumab", "category_terms": [ "alemtuzumab", "lemtrada" ], "article_count": 116 } ] }, { "article_id": 283231, "title": "Longitudinal determinants of employment status in people with relapsing-remitting multiple sclerosis", "summary": "CONCLUSION: More depression, a higher impact of fatigue, more cognitive complaints and less workplace support are predictive of a deteriorated employment status after three years in individuals with MS. How these factors progress over time is not different between those with a stable or deteriorated employment. MS-related disability, anxiety, objective cognition and coping were not related to a deterioration in employment status.", "link": "https://pubmed.ncbi.nlm.nih.gov/38660124/?fc=20210216052009&ff=20240425112532&v=2.18.0.post9+e462414", "published_date": "2024-04-25T10:00:00Z", "source": "PubMed", "publisher": "Elsevier BV", "container_title": "IBRO Neuroscience Reports", "authors": [ { "author_id": 247340, "given_name": "E.E.A.", "family_name": "van Egmond", "ORCID": null, "country": null }, { "author_id": 247365, "given_name": "K.", "family_name": "van der Hiele", "ORCID": null, "country": null }, { "author_id": 348905, "given_name": "M.J.", "family_name": "de Rooij", "ORCID": null, "country": null }, { "author_id": 247352, "given_name": "D.A.M.", "family_name": "van Gorp", "ORCID": null, "country": null }, { "author_id": 247356, "given_name": "P.J.", "family_name": "Jongen", "ORCID": null, "country": null }, { "author_id": 247357, "given_name": "J.J.L.", "family_name": "van der Klink", "ORCID": null, "country": null }, { "author_id": 247359, "given_name": "M.F.", "family_name": "Reneman", "ORCID": null, "country": null }, { "author_id": 247342, "given_name": "E.A.C.", "family_name": "Beenakker", "ORCID": null, "country": null }, { "author_id": 247343, "given_name": "J.J.J.", "family_name": "van Eijk", "ORCID": null, "country": null }, { "author_id": 247345, "given_name": "S.T.F.M.", "family_name": "Frequin", "ORCID": null, "country": null }, { "author_id": 247347, "given_name": "K.", "family_name": "de Gans", "ORCID": null, "country": null }, { "author_id": 262394, "given_name": "E.", "family_name": "Hoitsma", "ORCID": null, "country": null }, { "author_id": 247350, "given_name": "O.H.H.", "family_name": "Gerlach", "ORCID": null, "country": null }, { "author_id": 348906, "given_name": "J.P.", "family_name": "Mostert", "ORCID": null, "country": null }, { "author_id": 247361, "given_name": "W.I.M.", "family_name": "Verhagen", "ORCID": null, "country": null }, { "author_id": 247363, "given_name": "L.H.", "family_name": "Visser", "ORCID": null, "country": null }, { "author_id": 247362, "given_name": "H.A.M.", "family_name": "Middelkoop", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-25T11:25:42.272630Z", "noun_phrases": null, "doi": "10.1016/j.ibneur.2024.04.002", "access": "open", "takeaways": "After 3 years, depression, fatigue, cognitive complaints and less workplace support are predictive of a deteriorated employment status in people with MS. MS", "categories": [] }, { "article_id": 283230, "title": "Effects of exercise in people with multiple sclerosis: a systematic review and meta-analysis", "summary": "<jats:sec><jats:title>Background</jats:title><jats:p>A growing body of studies have examined the effect of exercise in people with multiple sclerosis (MS), while findings of available studies were conflicting. This meta-analysis aimed to explore the effects of exercise on balance, walking ability, walking endurance, fatigue, and quality of life in people with MS.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We searched PubMed, Web of Science, Scopus, and Cochrane databases, through March 1, 2024. Inclusion criteria were: (1) RCTs; (2) included an intervention and control group; (3) had people with MS as study subjects; (4) had balance, walking ability, walking endurance, fatigue, or quality of life as the outcome measures. Exclusion criteria were: (1) non-English publications; (2) animal model publications; (3) review articles; and (4) conference articles. A meta-analysis was conducted to calculate weighted mean difference (WMD) and 95% confidence interval (CI). Cochrane risk assessment tool and Physiotherapy Evidence Database (PEDro) scale were used to evaluate the methodological quality of the included studies.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Forty studies with a total of 56 exercise groups (<jats:italic>n</jats:italic> = 1,300) and 40 control groups (<jats:italic>n</jats:italic> = 827) were eligible for meta-analysis. Exercise significantly improved BBS (WMD, 3.77; 95% CI, 3.01 to 4.53, <jats:italic>P</jats:italic> < 0.00001), TUG (WMD, −1.33; 95% CI, −1.57 to −1.08, <jats:italic>P</jats:italic> < 0.00001), MSWS-12 (WMD, −2.57; 95% CI, −3.99 to −1.15, <jats:italic>P</jats:italic> = 0.0004), 6MWT (WMD, 25.56; 95% CI, 16.34 to 34.79, <jats:italic>P</jats:italic> < 0.00001), fatigue (WMD, −4.34; 95% CI, −5.83 to −2.84, <jats:italic>P</jats:italic> < 0.00001), and MSQOL-54 in people with MS (WMD, 11.80; 95% CI, 5.70 to 17.90, <jats:italic>P</jats:italic> = 0.0002) in people with MS. Subgroup analyses showed that aerobic exercise, resistance exercise, and multicomponent training were all effective in improving fatigue in people with MS, with resistance exercise being the most effective intervention type. In addition, a younger age was associated with a larger improvement in fatigue. Furthermore, aerobic exercise and multicomponent training were all effective in improving quality of life in people with MS, with aerobic exercise being the most effective intervention type.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Exercise had beneficial effects in improving balance, walking ability, walking endurance, fatigue, and quality of life in people with MS. Resistance exercise and aerobic exercise are the most effective interventions for improving fatigue and quality of life in people with MS, respectively. The effect of exercise on improving fatigue was associated with the age of the participants, with the younger age of the participants, the greater the improvement in fatigue.</jats:p></jats:sec><jats:sec><jats:title>Systematic review registration</jats:title><jats:p><jats:ext-link>https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=371056</jats:ext-link>, identifier: CRD42022371056.</jats:p></jats:sec>", "link": "https://pubmed.ncbi.nlm.nih.gov/38660348/?fc=20210216052009&ff=20240425112532&v=2.18.0.post9+e462414", "published_date": "2024-04-25T10:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Public Health", "authors": [ { "author_id": 285144, "given_name": "Liwen", "family_name": "Du", "ORCID": null, "country": null }, { "author_id": 348902, "given_name": "Haoyu", "family_name": "Xi", "ORCID": null, "country": null }, { "author_id": 285143, "given_name": "Shiyan", "family_name": "Zhang", "ORCID": null, "country": null }, { "author_id": 348903, "given_name": "Yilun", "family_name": "Zhou", "ORCID": null, "country": null }, { "author_id": 348904, "given_name": "Xifeng", "family_name": "Tao", "ORCID": null, "country": null }, { "author_id": 185375, "given_name": "Yuanyuan", "family_name": "Lv", "ORCID": "http://orcid.org/0000-0002-4397-8768", "country": null }, { "author_id": 285140, "given_name": "Xiao", "family_name": "Hou", "ORCID": null, "country": null }, { "author_id": 185376, "given_name": "Laikang", "family_name": "Yu", "ORCID": "http://orcid.org/0000-0001-7649-5095", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-25T11:25:40.953655Z", "noun_phrases": null, "doi": "10.3389/fpubh.2024.1387658", "access": "open", "takeaways": null, "categories": [] }, { "article_id": 283229, "title": "Emotional dyscontrol in multiple sclerosis: an opinion article", "summary": "No abstract", "link": "https://pubmed.ncbi.nlm.nih.gov/38660389/?fc=20210216052009&ff=20240425112532&v=2.18.0.post9+e462414", "published_date": "2024-04-25T10:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Behavioral Neuroscience", "authors": [ { "author_id": 348900, "given_name": "Mara", "family_name": "Palumbo", "ORCID": null, "country": null }, { "author_id": 348901, "given_name": "Sara", "family_name": "Palumbo", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-25T11:25:39.896462Z", "noun_phrases": null, "doi": "10.3389/fnbeh.2024.1376021", "access": "open", "takeaways": null, "categories": [] }, { "article_id": 283228, "title": "Glomerulonephritis after Alemtuzumab Treatment for Multiple Sclerosis: A Report of Two Cases", "summary": "<jats:p>Introduction: \n\nAlemtuzumab, a humanized monoclonal antibody indicated for the treatment of adult patients with active relapsing-remitting multiple sclerosis (MS), has been associated with increased risk of autoimmune adverse events, including thyroid disorders, immune thrombocytopenia, and renal diseases. Renal immune-mediated adverse events, which has been reported in 0.3% of patients treated with alemtuzumab in MS clinical trials, typically occur within 39 months after the last drug administration. However, no consensus has been reached regarding the management of patients who develop glomerulonephritis after treatment with alemtuzumab. \n\nCase Presentation:\n\nWe report the cases of two young adults with MS who developed biopsy-proven severe glomerulonephritis after alemtuzumab treatment. Both patients, including a 32-year-old female patient who developed membranous nephropathy and a 31-year-old male who developed drug-induced podocytopathy, were treated successfully with the calcineurin inhibitor tacrolimus followed by the anti-CD20 antibody rituximab. \n\nConclusion:\n\nRegular renal function monitoring is required in patients who may rarely develop glomerulonephritis following treatment with alemtuzumab. There is no clear consensus on case management. In both cases, immunosuppressive therapy, which was necessary due to disease severity, resulted in successful remission, highlighting the potential utility of this approach. \n</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38660579/?fc=20210216052009&ff=20240425112532&v=2.18.0.post9+e462414", "published_date": "2024-04-25T10:00:00Z", "source": "PubMed", "publisher": "S. Karger AG", "container_title": "Glomerular Diseases", "authors": [ { "author_id": 348897, "given_name": "Abdullah", "family_name": "Al-Muhaiteeb", "ORCID": null, "country": null }, { "author_id": 348898, "given_name": "Kamal", "family_name": "Alkeay", "ORCID": null, "country": null }, { "author_id": 348899, "given_name": "Ahmad", "family_name": "Altaleb", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-25T11:25:38.797624Z", "noun_phrases": null, "doi": "10.1159/000538492", "access": "open", "takeaways": "Alemtuzumab is a humanized monoclonal antibody indicated for the treatment of adult patients with active relapsing-remitting multiple sclerosis (MS). It has been associated with increased risk of autoimmune adverse events, including thyroid disorders, immune thrombocytopenia, and renal diseases. Renal immune-mediated adverse events typically occur within 39 months after the last drug administration. There is no consensus on the management", "categories": [ { "category_id": 2, "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/", "category_name": "Alemtuzumab", "category_slug": "alemtuzumab", "category_terms": [ "alemtuzumab", "lemtrada" ], "article_count": 116 } ] }, { "article_id": 283227, "title": "Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data", "summary": "CONCLUSION: Real-world evidence suggested that montelukast reduces MS relapses, warranting future clinical trials and further research on LTRAs' potential mechanism in MS.", "link": "https://pubmed.ncbi.nlm.nih.gov/38660773/?fc=20210216052009&ff=20240425112532&v=2.18.0.post9+e462414", "published_date": "2024-04-25T10:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-25T11:25:37.852808Z", "noun_phrases": null, "doi": "10.1177/13524585241240398", "access": "restricted", "takeaways": "", "categories": [] } ] }